The Organ Manufacturing and Regenerative Medicine Project will be focused initially on the heart and heart disease. Cardio Vascular Diseases (CVD) are the number one cause of death globally: more people die annually from CVDs than from any other cause. An estimated 17.3 million people died from CVDs in 2008, representing 30% of all global deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease and 6.2 million were due to stroke. By 2030, almost 23.6 million people will die from CVDs, mainly from heart disease and stroke. These are projected to remain the single leading causes of death. Additionally, dozens of drugs and billions of dollars have been spent combating heart disease.
Regenerative medicine is a young but promising research ﬁeld. Regenerative medicine has already proven beneﬁcial in patients with heart disease. When the heart becomes diseased or damaged it gets weakened and is unable to pump the volume of blood necessary to the rest of the body. Sometimes the heart stops all together resulting in a heart attack. Stem cells have been proven to help rebuild a damaged or diseased heart but sometimes the heart is so damaged that a transplant is called for. If a brand new heart could be manufactured using the patient’s cells, this kind of transplant would be more successful than artiﬁcial or donor heart transplants are today. The goals of the Organ Manufacturing project are to harness the healing power of stem cells, and to perfect organ manufacturing and transplantation in humans. The Cure Is Now will begin with the heart and then move to other vital organs such as the liver, lungs, kidneys etc.
Developments have been in: regenerated vasculature, successful bioreactor technology and transplantation technique.
The initial approach will be to harvest stem cells in the least invasive way possible and then transform them into cardiac stem cells. Safe and eﬀective injection of these cells into or next to the heart in such away that the stem cells beneﬁt the injured heart will be perfected.
The next step will be to grow a viable heart in the lab followed by transplantation into humans.
The Cure Is Now Organ Manufacturing and Regenerative Medicine team will eventually move their focus to other vital organs.
This project will include various kinds of studies. Inpatient and outpatient facilities will be required among other types of facilities. Microscopes, cell medium and pathology facilities would be required. Organ regeneration and transplantation into humans will require decellularized organ scaﬀolds, stem cell harvesting and growth equipment in a sterile environment, in vivo or in vitro bio reactors will be required and out and inpatient facilities will be utilized.
The Injectable Stem Cell Pilot project and the Organ Regeneration and transplantation project Pilot the goal with these projects will be to bring this model into humans.
Research materials: $100,000/year
Regeneration Apparatus: $200,000/year
One-‐oﬀ expenses: Computers: $105,000
Equipment (hoods, etc.): $550,000
Project Annual Total: $1,495,000